The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

We’ve seen the first AI-generated commercials, songs and even social media influencers outside of healthcare. Will pharma be ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2026. | In this tracker, Fierce Pharma is recording the ...

Pharma faces regulations and stringent rules for transparency, but the payoff is drugs that can get to market faster and ...

AI is no longer a distant concept; it is reshaping industries today. For pharmaceutical companies, the question is clear: how ...

Chinese companies are no longer just powering the pharma industry from behind the scenes, or solely churning out “me too” ...

HLP003 (previously referred to as CYB003): a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy ...

Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular in the first mo | Of the top 10 biopharma M&A deals of 2025, six ...

While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A ...

What defined pharma in 2025? Contract Pharma’s most‑viewed breaking news offers insights. Here’s your yearly recap—the most ...